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remains, and their predictive value regarding long-term graft 
function often shows conflicting results (2-5). We aimed to an-
alyze the baseline biopsy histological findings, together with 
patient and donor characteristics, to determine if there were 
any correlations that could predict long-term outcomes (renal 
function and graft and patient survival).
Methods
Selection of patients
We analyzed 601 successive kidney transplants (from 
brain death or live related donors) performed at the Agostino 
 Gemelli Policlinic (Sacred Heart Catholic University, Rome,  Italy) 
between January 1997 and July 2012, using data retrieved 
from clinical charts. In 284 cases (47%), a PIB had been per-
formed. For each biopsy, a semiquantitative scale previously 
reported by Karpinski et al (6) and used by Remuzzi (1, 7) was 
used to obtain intensity (from 0 to 3), of glomerular sclerosis 
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Introduction
Facing the reality of the scarcity of kidney donors, preim-
plantation biopsies (PIBs; time-zero biopsies) are commonly 
used to refuse a potential deceased donor or to decide wheth-
er a single versus double kidney transplantation (KTX) should 
be performed (1). However, a lack of information about 
the prognostic importance of these findings in follow-up still 
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(GS), arteriolosclerosis (AS), interstitial fibrosis (IF) and tubu-
lar atrophy (TA). We noticed that around two thirds of biop-
sies, in each category of histopathological feature (GS, IF, AS 
or AT), presented grade 0 (absence of pathological findings). 
The sum of the 4 degrees was named the implantation biop-
sy score (IBS) (1). To establish comparisons, we determined 
2 groups according to IBS: 1 with lower Remuzzi scores, under 4 
(IBS 0-3), and another with higher IBS, equal to or greater than 
4 (IBS 4-6), with 6 the highest score accepted.
Endpoints
Primary end points were death-censored 5-year graft 
survival; secondary end points were overall graft and patient 
survival. Except where indicated, graft losses were censored 
at death. Minimum follow-up was 1 year; maximum 16 years.
Clinical data
Demographic aspects of recipients and their respective do-
nors (age, sex, weight, height, body mass index) were deter-
mined for each donor–recipient pair. Dialysis antecedents were 
recorded (cause of chronic kidney failure, dialysis duration, re-
transplant). Previous diabetes, hypertension or dyslipidemia 
diagnosis were according to current standard literature defini-
tions (8, 9). Donor death cause was registered; cerebrovascular 
accidents (CVA) included ischemic or hemorrhagic events. Cold 
ischemia time (CIT) and sum of HLA mismatches for broad an-
tigens of locus A, B and DR serotypes are shown. Creatinine 
clearance was estimated (estimated glomerular filtration rate 
[eGFR]) in donors by Cockcroft-Gault formula (at procurement) 
(10); in recipients, by the abbreviated Modification of Diet in 
Renal Disease (aMDRD) study equation (at 1st, 3rd and 5th year) 
(11). Delayed graft function (DGF) was defined as need for dial-
ysis after kidney transplantation (4, 12). Immediate graft func-
tion was the lack of postoperative dialysis need (4). Primary 
nonfunction was a never-functioning kidney after transplant, 
in which dialysis was never discontinued.
Donor classification
Donors were standard or nonstandard; the latter was de-
fined according to the standard for an expanded criteria do-
nor (ECD), which followed United Network for Organ Sharing 
(UNOS) criteria (age >59 years; or age 50-59 years, PLUS 2 of 
the following: death caused by cerebrovascular accident [CVA], 
terminal creatinine >1.5 mg/dL or history of hypertension) 
(13). We also determined deceased donor score (DDS) which 
considers 5 donor characteristics and points to each variable, 
which are then classified into grades (A = 0-9 points; B = 10-19; 
C = 20-29; and D = 30-39), with grades C and D considered as 
“marginal” donors (14).
Histological evaluation
Criteria for sample validation were based on glomerular 
count (≥20, or at least 10 in each kidney from same donor). 
Biopsy samples were almost always obtained by wedge sec-
tion; results in ECDs were available at time of organ allocation 
and helped to accept/reject a donor. Before 2009, readings 
were performed by each donor center (i.e., the local pa-
thologist); after 2009, donor biopsies were obtained and 
send to a centrally based pathologist. Readings were from 
frozen slides, with 2 to 4 hematoxylin-eosin (H&E)-stained 
sections available for review. The remnant specimens were 
postfixed in formalin and paraffin-embedded (FFPE) and 
revaluated with H&E, periodic acid–Schiff, Wright and Mas-
son’s trichrome stained sections in all samples in the daily 
routine.
Statistical analysis
Categorical variables were compared using chi-square 
and numerical with Student’s t-test. Histological grades are 
discrete variables, but were considered as continuous for sta-
tistical analysis, as in previous similar works (4, 15). Correla-
tions for 5-year death-censored graft survival were evaluated 
by Cox regression and diagnostic accuracy by area under the 
receiver operator characteristic curve (AUC ROC). Patient and 
graft survival were analyzed using the Kaplan-Meier method. 
A p value of 0.05 or less was considered significant.
Bioethical aspects
This was a retrospective study and no intervention was 
planned before or after study concept. At time of inclusion in 
the waiting list and at the moment of transplant, informed con-
sent (previously approved by the local ethics committee) was 
appropriately presented and signed to permit patients to be 
submitted to any of the proposed interventions, using immu-
nosuppressive protocols approved by the ethics committee of 
the Catholic University of Rome. Patients were adequately in-
formed by the transplant multidisciplinary team and were free 
to participate or remove their consent at any of the phases.
Results
Implantation biopsy scores can theoretically vary from 0 
(normal kidney) to 12 (remarkable, severe alterations), but an 
IBS of 7 or more indicates nonviable kidneys (7), so scores in 
our cohort varied from 0 to 6 because study biopsies included 
only kidneys accepted for transplant and effectively implant-
ed. Karpinski score for implantation biopsies was originally 
created for deceased donors; we obtained a cutoff value for 
IBS plotting all of the values among deceased donors and es-
tablishing an AUC ROC. We noticed that the score value 3 had 
the higher sensitivity and specificity in determining graft loss 
(AUC = 0.674, p = 0.04); at the same time, we noticed that 
among live donors (which would be the gold standard for bi-
opsy findings), only 1 zero-hour biopsy had a score of 4.
Demographic characteristics
Table I shows demographic characteristics for each group 
of recipients (group IBS 0-3: n = 251; group IBS 4-6: n = 33). 
Mean age among group IBS 4-6, which concentrates ECD, was 
higher. This agrees with our regional allocation policy, in which 
old donors can be preferentially allocated to older recipients. 
Other studied characteristics are available in Table I, but differ-
ences between IBS 0-3 or IBS 4-6 were not significant. Donor 
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TABLE I - Kidney transplant recipient and donor characteristics according to groups defined by implantation biopsy score (IBS)
Characteristics IBS 0-3 (n = 251) IBS 4-6 (n = 33) p Value
Recipient Age, years 44.1 ± 12.2 53.5 ± 11.9 <0.001
Sex, male/female (%) 63.3/36.7 63.2/37.8 0.99
BMI 24 ± 3 25 ± 4 0.09
Dialysis time, years 4.4 ± 4.0 5.0 ± 4.5 0.43
Prior kidney transplant 6% 3% 0.50
Hypertension 74% 62% 0.13
Diabetes 7% 15% 0.08
Dyslipidemia 25% 31% 0.46
Primary kidney disease
Immunological 26% 25% 0.90
Polycystic kidney disease 18% 16% 0.74
Urological/infective 11% 3% 0.17
Other 45% 56% 0.23
Donor Age, years 42 ± 15 57 ± 14 <0.001
Type, deceased/live 93.5/6.5% 96.7/3.3% 0.50
CVA as donor death cause 54% 62% 0.37
Creatinine at procurement 1.0 ± 0.5 1.0 ± 0.6 0.41
Donor eGFR 109 ± 60 91 ± 45 0.13
Hypertension 18% 41% 0.003
HLA mismatches (A+B+DR) 2.6 ± 1.1 2.8 ± 0.9 0.32
% PRA, max. (95% CI min-max) 5 ± 16 (0-9) 2 ± 5 (0-6) 0.29
ECD, nonstandard 23% 63% <0.001
DDS score 12.7 ± 8.8 21.3 ± 9.6 <0.001
DDS marginal 26% 65% <0.001
Cold ischemia time, hours 12.3 ± 5.0 15.1 ± 5.2 0.005
Preimplantation  
biopsy
Glomerulosclerosis grade (max-min) 0.35 ± 0.49 (0-2) 1.03 ± 0.66 (0-3) <0.001
Interstitial fibrosis grade (max-min) 0.28 ± 0.46 (0-2) 0.97 ± 0.41 (0-2) <0.001
Arteriolosclerosis grade (max-min) 0.17 ± 0.41 (0-3) 1.37 ± 0.66 (0-3) <0.001
Tubular atrophy grade (max-min) 0.33 ± 0.47 (0-1) 0.93 ± 0.25 (0-1) <0.001
Final score IBS (GS + IF + AS + AT) (max-min) 1.12 ± 1.12 (0-3) 4.30 ± 0.53 (4-6) <0.001
Follow-up Duration, years 7.1 ± 3.7 7.2 ± 4.3 0.96
Delayed graft function 28% 46% 0.043
Primary nonfunction 1% 10% <0.001
Renal function* eGFR after 1 year 52 ± 20 39 ± 28 0.002
eGFR after 3 years 52 ± 21 41 ± 32 0.015
eGFR after 5 years 50 ± 25 40 ± 34 0.086
Graft survival after 1 year 96.0% 84.4% 0.006
after 5 years 93.2% 78.1% 0.004
Overall 88.8% 75.0% 0.028
Patient survival after 1 year 99.6% 96.9% 0.08
after 5 years 98.0% 93.8% 0.14
Overall 95.6% 90.6% 0.22
BMI = body mass index; CVA = cerebrovascular accident; DDS = deceased donor score; ECD = extended-criteria donor; eGFR = estimated glomerular filtration 
rate; HLA = human leukocyte antigens; PRA = panel reactive antibody.
* CrCl: creatinine clearance, estimated by abbreviated Modification of Diet in Renal Disease (aMDRD) study equation (mL/min per 1.73 m2).
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age and history of hypertension were higher in group 2. Non-
standard donors (by ECD or DDS definitions) were higher in 
the group with higher IBS values. However, donor creatinine 
levels (i.e., eGFR at time of allocation), as other donor charac-
teristics, were similar among groups (Tab. I).
Donor quality score systems
Sixty-three percent of donors with IBS 4-6 were defined as 
ECD according to UNOS classification, versus 23% among IBS 
0-3 (p<0.001). In our cohort, ECD and DDS were able to predict 
graft function in all proposed time points (at time of discharge, 
6th month, 3rd and 5th year after transplant; data not shown). 
Relative risk (RR) of graft failure during follow-up (overall) for 
presence of ECD was 2.3 (p = 0.028, 95% confidence interval 
[95% CI], 1.1-4.9), and for DDS, 3.3 (p = 0.001; 95% CI, 1.6-7.3). 
Only DDS (but not ECD) increased RR for patient survival during 
overall follow-up (RR = 3.5; p = 0.028; 95% CI, 1.1-11.4). Cold 
ischemia times were superior in group IBS 4-6.
Delayed graft function
DGF was present in 46% of ECD and 28% of standard do-
nors (chi-square p = 0.043, RR 2.1, CI 95% 1.01-4.7). DGF was 
present in 30% of patients (higher when IBS 4-6); primary non-
function was higher among IBS 4-6. See Table I for p values. 
Considering the 4 components of time-zero scores, interstitial 
fibrosis (IF) of any grade (41.6 vs. 25.8% arteriolosclerosis (AS) 
IF = 0; p = 0.018, relative risk [RR] = 1.8, 95% CI, 1.1-3.1), pres-
ence of AS of any grade (53% vs. 23.6% with AS = 0; p<0.001, 
RR = 3.6, 95% CI, 2.0-6.5) and presence of a final time-zero 
score above or equal to 4 (46.7% vs. 28.6% for final score <4; 
p = 0.043, RR = 2.2, 95% CI, 1.0-4.7). DGF and presence of any 
grade of GS or TA were not significant. Time of CIT longer than 
18 hours was associated with DGF (55.6% vs. 26.5% when CIT 
was <18 hours; p<0.001, RR = 3.4, 95% CI, 1.7-7.1).
Follow-up data
Duration of observation period in years was similar in both 
groups. Graft function at different times after transplant was 
estimated by aMDRD function as shown in Table I. In the IBS 
0-3 group, eGFR was superior in the 1st, 3rd but not the 5th year. 
Graft survival (death censored at 1st and 5th year) and graft sur-
vival during the study were superior in group IBS 0-3. However, 
regarding patient survival, differences between groups do not 
persist (Tab. I).
Implantation biopsy scores: sensitivity and specificity
In 3 situations we analyzed the ability of IBS performance 
to identify (A) suboptimal donors (nonstandard donors), (B) 
worst creatinine clearances at discharge after KTX (grades 
IV-V, eGFR by aMDRD under 30 mL/min) and (C) prediction of 
graft and patient outcomes at 5 years. In all 3 situations, we 
saw that IBS ≥4 (or IBS 4-6) presented low sensitivity (SENS) 
but high specificity (SPEC): (A) SENS 25%, SPEC 94%, odds ra-
tio (OR) P = 5.4 (95% CI, 2.4-12.3), p = 0.001; (B): SENS 28%, 
SPEC 93%, OR = 5.5 (95% confidence interval (CI), 2.4-12.2), 
p<0.001; (C) predictive for graft, but not for patient survival; 
SENS 21%; SPEC 90%, OR = 2.7 (95% CI, 1.1-6.9), p = 0.03. 
Performance of donor creatinine above 1.5 mg/dL and Cre-
atinine clearance under 55 mL/min in predicting A, B and C 
outcomes also presented high SPEC and low SENS. Traditional 
criteria of donor creatinine >1.5 mg/dL (used with other ele-
ments) to declare a procured donor as a nonstandard donor, 
did not predict graft function, graft survival or patient sur-
vival. IBS showed a better profile in terms of OR. Regarding 
survival outcomes, only IBS was able to predict graft losses at 
5 years (estimated relative risk of graft loss was 2.7). No donor 
characteristics predicted patient survival well (see below).
Correlations for death-censored graft survival and accuracy
We analyzed the demographic, clinical, preimplantation bi-
opsies (PIB) features shown in Table I, selecting only those vari-
ables that were originally statistically significant among groups. 
The results can be seen in Table II. We performed a univariate 
Cox regression considering the whole cohort (284 patients) 
for each characteristic to identify the hazard ratios (expected 
beta-value) and respective p values in predicting 5-year death-
censored graft survival. For all characteristics, diagnostic ac-
curacy was estimated by c-values (determinate by AUC ROC). 
In this setting, one can observe that there are many character-
istics that are correlated with graft survival, once the p value 
of Cox analysis is significant. For PIBs, grade of GS, IF and final 
IBS (GS+IF+AS+AT) showed a significant correlation with 5-year 
death-censored graft survival. However, significant diagnostic 
accuracy was shown only for donor history of hypertension, 
DDS score “marginal,” grade of IF on PIB, group of IBS score and 
primary nonfunction. Grade of IF presented the highest c-value 
(0.77) among these variables. Among demographic character-
istics, only age of recipient was accurate accurately correlated 
with 5-year patient survival (c = 0.89, p = 0.02, data not shown). 
Other advantages of organ quality information to physicians giv-
en by PIBs are available online. We present a prediction model 
of graft survival using biopsy data among other characteristics 
(Supplementary Tab. I and Fig. 1, available online at www.poin-
tofcarejournals.com/poc/napoc).
Graft survival
We analyzed 5-year graft survival by Kaplan-Meier anal-
ysis, comparing curves between groups IBS 0-3 and IBS 4-6 
(Fig. 1). We observes that implantation biopsy scores above 
or equal to 4 (IBS 4-6) predicted a less favorable graft survival 
(p = 0.04). A sudden slope before the 1st year was seen during 
group 2 follow-up, a difference that remained throughout the 
observation period without significant changes. To explore 
this finding, we observed the 5-year estimated graft survival, 
censored for early graft losses, and found that the difference 
disappeared (Fig. 1). This means that IBS scores are important 
to predict early graft losses in IBS 4-6, but after these initial 
losses, the remaining kidneys are lost at a similar rate to that 
observed in IBS 0-3 during the first 5 years of follow-up.
Discussion
Donor biopsies are useful to give baseline information 
about histological quality of the donor to make comparisons 
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with subsequent biopsies, helping to discriminate donor-
derived lesions from de novo alterations (2). Disparities be-
tween need for and availability of organs has increased the 
use of ECDs (16). In United States, up to 85% of procured ECD 
kidneys are biopsied (2, 17). High grade of glomerulosclerosis 
is a good predictor of early graft dysfunction (3), so this find-
ing usually leads to organ discharge (18). Despite glomerulo-
sclerosis is an important feature to allocation decision (1), its 
grade in effectively transplanted kidneys does not seem to be 
predictive of DGF or long-term kidney function in our series. 
This is probably an effect of organ procurement practices, se-
lecting better GS scores, avoiding an effect on graft outcome 
(5, 15). Better prognostic information is given in specific 
donor subsets (older donors, with hypertension, diabetes, 
TABLE II -  Correlations for 5-year death-censored graft survival (Cox regression) and diagnostic accuracy (AUC ROC)
Correlation with 5-year  
death-censored graft survival
Accuracy of 5-year  
death-censored graft survival
Characteristic Hazard ratio p Value AUC ROC p Value
Recipient Age, years 1.01 0.52 0.928 <0.001
Donor Age, years 1.02 0.06 0.693 0.005
Hypertension 0.37 0.042 0.716 0.002
ECD (nonstandard) 0.40 0.06 0.716 0.003
DDS Score 1.05 0.036 0.620 0.10
DDS “marginal” 0.35 0.035 0.678 0.014
Cold ischemia time, hours 1.05 0.29 0.923 <0.001
Preimplantation  
biopsy
GS 1.88 0.08 0.746 <0.001
IF 2.28 0.043 0.773 <0.001
AS 1.71 0.07 0.800 <0.001
AT 1.71 0.22 0.928 <0.001
Final IBS (GS + IF + AS + AT) 1.42 0.014 0.619 0.08
Group of IBS score (0-3 vs. 4-6) 0.25 0.003 0.659 0.021
Follow-up Delayed graft function 0.24 0.003 0.508 0.91
Primary nonfunction 0.01 <0.001 0.718 0.002
Estimated GFR after 1 year 0.82 <0.001 0.973 <0.001
Estimated GFR after 3 years 0.81 <0.001 0.983 <0.001
AS = arteriolosclerosis grade; AT = tubular atrophy grade; AUC ROC = area under the receiver operator characteristic curve; DDS = deceased donor score;  
ECD = extended criteria donor; GS = glomerulosclerosis grade; IBS = implantation biopsy score; IF = interstitial fibrosis grade.
Fig. 1 - (A) Five-year death-censored 
graft survival; (B) 5-year death- and 
primary nonfunction–censored. IBS = 
implantation biopsy score. 
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cardiovascular disease or abnormal creatinine) (3, 19). In our 
study, the presence of interstitial fibrosis correlated well with 
worst results in long-term graft survival (chi-square p = 0.029; 
RR = 2.23; 95% CI, 1.07-4.64). These findings are similar to 
those of Lopes et al (15), who found a positive correlation 
between IF and serum creatinine at 3 and 6 months but no 
correlation with TA, GS or AS.
Many authors assume that none of the histological vari-
ables and scores provide perfect predictions and so results 
should be interpreted in the context of all available informa-
tion on donor–recipients (2, 18). A histological score is not 
the first test used during organ procurement to accept a kid-
ney, but it is used successively to discard one. To establish 
a prediction ability for IBS score, we needed a cutoff value 
that could reflect a high specificity (even losing sensitivity 
to some extent). Some arguments against routine time-zero 
biopsies are that the performance of the PIB itself can in-
crease the odds of a discard (2, 20) or that the procedure 
itself generates a further delay in the graft implantation (for 
collection, process and interpretation), increasing the cold-
ischemia time and the risk of DGF (2, 21). Most of recent pa-
pers describe the experience in performing PIBs among ECD 
donors. The strongest point of this work is that PIB was per-
formed not only among ECDs, but also in standard deceased 
donors. A biopsy in this case was able to identify that at least 
5.8% of “standard” deceased donors according to UNOS clas-
sification have in fact a histological score ≥4 (11/189). We 
also observed that ECD donors have a 5 times higher risk 
of having a preimplant score above 4 when compared with 
non-ECD donors (p<0.001; RR = 5.5; 95% CI, 2.4-12.3). Using 
the DDS score (14), we obtained very similar results (5.2% 
of “standard” deceased donors with final score >4 [9/173]; 
p<0.001; RR = 5.4; 95% CI, 2.3-12.8).
DGF can be predicted by PIB (5); it increases morbidity and 
may lead to premature graft failure, longer hospitalization and 
higher health care costs (this is especially true among ECDs). 
Regarding the better performance of nonstandard donor 
scores, we determined the AUC ROC comparing ECD or DDS 
classification, using final histological score above 4 as the state 
variable; both AUC ROC were similar (r = 0.695 for ECD and 
r = 0.698 for DDS, p = 0.001 for both). The same comparison 
was made using graft outcome at the end of follow-up as state 
variable; again AUC ROC were similar (c = 0.643 and c = 0.642, 
p = 0.012 and p = 0.013, for ECD and DDS, respectively). ROC 
curves for IBS ≥4 present a low c value. However, IBS hallmark 
information is due to its specificity, which is higher enough that 
alone it can predict early graft function and long-term graft 
survival. Another piece of information about IBS is that the 
SENS of IBS scores ≥4 are 2 to 3 times higher than the SENS of 
donor creatinine in predicting acute dysfunction. Concluding, 
our results showed that the most important isolated histologi-
cal finding, in effectively transplanted grafts, is the grade of IF. 
IBS 4-6 can determine an increased risk of early graft loss, es-
pecially primary nonfunction. Higher IBS grades predict lower 
graft function until the 3rd postoperative year; but in this cohort 
is not able not predict graft function at the 5th postoperative 
year. after this, we probably need a higher number of patients 
to demonstrate the difference (numerically but not statisti-
cally different). Possibly, as graft survival advances, recipient 
characteristics (including therapy, immunological events and 
 comorbidities) could gain more importance in determining 
renal function, surpassing any influence of IBS. Moreover, IBS 
predicts graft survival at 1 and 5 years after transplant, but 
does not predict patient survival.
A last word about PIBs in live donors. Nowadays, biopsies 
can be considered a graft survival prediction tool, with high 
specificity (despite a low sensitivity). Since the cyclosporine 
era of immunosuppression, we have dramatically reduced 
the impact of allograft acute rejections, remaining with late 
losses due to chronic allograft dysfunction (25). This has be-
come the most important problem in solid organ transplants, 
mediated by a myriad of etiopathological mechanisms and 
without specific treatment (22, 23). To obtain complete in-
formation about chronicity findings at long-term follow-up, a 
baseline biopsy is essential. This includes the need to perform 
biopsies not only in deceased ECDs, but also among living el-
derly donors, young living donors or deceased standard do-
nors (24). Virtually any type of donor can have unsuspected 
disease (GS, glomerulopathy, chronic vascular disease/AS, TA 
or IF) only revealed by a PIB. So, presentation of both donor 
types was intentional, not done unawares. Despite the fact 
that this was a small proportion of cases (<5% of studied pa-
tients), live donors were intentionally included to stress the 
importance of performing PIBs even in them. Table I shows 
there was no difference between deceased/live donor pro-
portion (6.6% vs. 3.3%) among groups (chi-square p = 0.5).
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